Meridian Bioscience (VIVO) Tops Q2 EPS by 8c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $2.60 --0%
Financial Fact:
General and administrative: 7.98M
Today's EPS Names:
ZVOI, SYRS, ATRA, More
Financial Fact:
General and administrative: 7.98M
Today's EPS Names:
ZVOI, SYRS, ATRA, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.56, $0.08 better than the analyst estimate of $0.48. Revenue for the quarter came in at $85.3 million versus the consensus estimate of $84.5 million.
GUIDANCE:
Meridian Bioscience sees FY2021 EPS of $1.60-$1.80, versus the consensus of $1.66. Meridian Bioscience sees FY2021 revenue of $305-335 million, versus the consensus of $324 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BrightSpring Health Services, Inc. (BTSG) Tops Q3 EPS by 34c ; Offers Guidance
- TFS Financial (TFSL) Reports In-Line Q4 EPS
- Jefferies Reiterates Buy Rating on InterGlobe Aviation Ltd. (INDIGO:IN)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
